

1 **Estimating historical impacts of vaccination against influenza B/Yamagata in the United States**  
2 **to inform possible risks of re-emergence in the absence of vaccination.**

3 Sinead E. Morris<sup>a,b,\*</sup>, Sarabeth M. Mathis<sup>a</sup>, Jessie R. Chung<sup>a</sup>, Brendan Flannery<sup>a</sup>, Alissa O’Halloran<sup>a</sup>,  
4 Catherine H. Bozio<sup>a</sup>, Peng-Jun Lu<sup>c</sup>, Tammy A. Santibanez<sup>c</sup>, Peter Daly<sup>a</sup>, Angiezel Merced-Morales<sup>a</sup>, Krista  
5 Kniss<sup>a</sup>, Alicia Budd<sup>a</sup>, Lisa A. Grohskopf<sup>a</sup>, Carrie Reed<sup>a</sup>, Matthew Biggerstaff<sup>a</sup>, A. Danielle Iuliano<sup>a</sup>

6  
7 <sup>a</sup>*Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, USA, 30329*

8 <sup>b</sup>*Goldbelt Professional Services, Chesapeake, VA, USA, 23320*

9 <sup>c</sup>*Immunization Services Division, Centers for Disease Control and Prevention, Atlanta, GA, USA, 30329*

10

11 **\*Corresponding author:** run7@cdc.gov

12

13 **Disclaimer:** The findings and conclusions in this report are those of the authors and do not necessarily  
14 represent the views of the Centers for Disease Control and Prevention.

15

16 **Abstract**

17 Influenza B/Yamagata viruses have not been detected globally since 2020 and will be removed from U.S.  
18 2024/25 seasonal influenza vaccines. We inferred impacts of vaccination against B/Yamagata from  
19 2016/17–2019/20 by combining B/Yamagata prevalence data with model-based estimates of disease  
20 burden prevented by vaccination against all influenza B viruses. B/Yamagata comprised approximately  
21 16–22% of positive virus specimens in 2016/17 and 2017/18, compared to 1% in 2018/19 and 2019/20.  
22 Across all seasons, we estimated that vaccination against B/Yamagata prevented 4.15 million illnesses,  
23 58,500 hospitalizations, and 4,070 deaths, and that 22.9 million B/Yamagata-associated illnesses,  
24 340,000 hospitalizations, and 25,100 deaths would have occurred without vaccination. Vaccination  
25 prevented the most B/Yamagata hospitalizations among adults ≥65 years but prevented the greatest  
26 percentage of B/Yamagata hospitalizations among children 6 months–4 years. Our results may help  
27 assess the potential impact if B/Yamagata were to recirculate in the absence of vaccination.

28

29 **Keywords:** vaccination; seasonal influenza; B/Yamagata; disease burden; vaccine-preventable burden

30

31 **Introduction**

32 Seasonal influenza vaccination is recommended for everyone ≥6 months who does not have  
33 contraindications in the United States (U.S.)<sup>1</sup>. Quadrivalent seasonal influenza vaccines which include  
34 antigens for two influenza B virus lineages, B/Yamagata and B/Victoria, have been available since 2013<sup>2</sup>.  
35 However, B/Yamagata viruses have not been detected globally since 2020 and will be removed from U.S.

36 vaccines starting in the 2024/25 season (although global surveillance for B/Yamagata will continue)<sup>3</sup>.  
37 Understanding the historical impact of vaccination against B/Yamagata is important to help assess the  
38 potential public health consequences if B/Yamagata were to recirculate in the absence of vaccine-  
39 mediated protection.

40 The U.S. Centers for Disease Control and Prevention (CDC) estimates disease burden prevented  
41 by influenza vaccination each season using a compartmental framework that accounts for vaccine  
42 effectiveness (VE), vaccination coverage, and time-varying risks of influenza exposure<sup>4</sup>. We have  
43 demonstrated an extension of this framework that partitions burden prevented by vaccination between  
44 influenza A and influenza B viruses<sup>5</sup>, and hypothesized that the latter estimates could provide insights  
45 into the impact of vaccination against B/Yamagata when combined with information on levels of  
46 B/Yamagata circulation.

47 To explore this, we identified information on B/Yamagata circulation in the United States for four  
48 seasons preceding its disappearance (2016/17–2019/20)<sup>6</sup>. These seasons ranged in epidemic severity  
49 from moderate (2016/17, 2018/19 and 2019/20) to high (2017/18)<sup>7</sup>, and in levels of B/Yamagata  
50 circulation<sup>8</sup>. We then combined this information with our reported estimates of influenza-associated  
51 disease burden and burden prevented by vaccination for both influenza B lineages. We estimated age-  
52 specific numbers of illnesses, hospitalizations, and deaths prevented by vaccination against B/Yamagata,  
53 and the corresponding number that would have been caused by B/Yamagata without vaccination. Our  
54 results may help inform efforts to assess potential future landscapes of influenza disease burden in the  
55 context of changing influenza B epidemiology and absence of vaccine protection against B/Yamagata.

56

## 57 **Methods**

### 58 *Surveillance data*

59 We obtained information on the prevalence of influenza B/Yamagata from 2016/17–2019/20 from CDC's  
60 FluView<sup>6</sup>. These data included the weekly number of influenza-positive specimens identified by virus  
61 type (influenza A or B), influenza A subtype, or influenza B lineage and reported by participating public  
62 health laboratories from the World Health Organization (WHO) Collaborating Laboratories System and  
63 National Respiratory and Enteric Virus Surveillance System (NREVSS). Data were available for five age  
64 groups: 0–4 years, 5–17 years, 18–49 years, 50–64 years, and ≥65 years. For each season,  $s$ , and age  
65 group,  $a$ , we calculated the prevalence of B/Yamagata among influenza B viruses,  $p_{a,s}$ , as the proportion  
66 of all influenza B specimens with known lineage that were positive for B/Yamagata. We also calculated  
67 prevalence among all influenza viruses (i.e., including influenza A viruses in addition to influenza B

68 viruses), as the proportion of all influenza specimens with known lineage or subtype that were positive  
69 for B/Yamagata.

70

### 71 *Framework for estimating burden prevented by vaccination for B/Yamagata*

72 We previously estimated disease burden and burden prevented by vaccination for all influenza B lineages  
73 from 2016/17–2019/20 by extending a compartmental framework developed by the CDC<sup>4,5</sup>. These  
74 estimates were generated for four disease severity categories (illnesses, medically-attended illnesses,  
75 hospitalizations, and deaths) and five age groups (6 months–4 years, 5–17 years, 18–49 years, 50–64  
76 years, and  $\geq 65$  years), and included uncertainty distributions obtained from Monte Carlo simulation.

77 For each age group ( $a$ ) and season ( $s$ ) we estimated disease burden and burden prevented by  
78 vaccination against B/Yamagata by multiplying our previous estimates for all influenza B lineages by the  
79 corresponding prevalence of B/Yamagata ( $p_{a,s}$ ). For example, if  $H_{a,s}$  is the estimated number of  
80 hospitalizations attributed to influenza B for age group  $a$  in season  $s$ , the number attributable to  
81 B/Yamagata was estimated as  $H_{a,s} \times p_{a,s}$ . Similarly, if  $HV_{a,s}$  is the estimated number of hospitalizations  
82 prevented by vaccination against influenza B, the number prevented by vaccination against B/Yamagata  
83 was estimated as  $HV_{a,s} \times p_{a,s}$ . To estimate burden that could have been caused by B/Yamagata in the  
84 absence of vaccination, we added the burden attributed to B/Yamagata with the estimated burden  
85 prevented by vaccination against B/Yamagata, for example,  $p_{a,s}(H_{a,s} + HV_{a,s})$ .

86 There was not a direct correspondence between the youngest age group of the B/Yamagata  
87 prevalence data and the influenza B burden estimates. We therefore assumed that B/Yamagata  
88 prevalence among children 0–4 years could approximate prevalence among children 6 months–4 years.  
89 Given the small sample size among age groups in some seasons (Table S1), we conducted an additional  
90 sensitivity analysis in which one population-wide value of B/Yamagata prevalence was applied across all  
91 ages. We also assumed that VE against influenza B was approximately equal to VE against B/Yamagata, so  
92 that estimates of burden prevented by vaccination against influenza B could be used to infer burden  
93 prevented by vaccination against B/Yamagata.

94 Finally, we constructed uncertainty distributions for the B/Yamagata burden estimates. First, we  
95 generated uncertainty around estimates of B/Yamagata prevalence using a Monte Carlo simulation  
96 approach described previously<sup>9,10,11</sup>. Briefly, we assumed prevalence for each age group and season  
97 followed a Binomially distributed random variable with probability of success equal to  $p_{a,s}$ . We  
98 generated 10,000 independent samples from this distribution,  $\hat{p}_{a,s,i}$ , and multiplied these by the Monte  
99 Carlo samples previously generated for each influenza B burden estimate (for example,  $\hat{H}_{a,s,i} \times \hat{p}_{a,s,i}$ , for

100  $i$  in 1, 2, ... 10,000). We describe uncertainty as the 95<sup>th</sup> percentiles of the resulting distributions. All in-  
101 text estimates are reported to three significant figures.


102

### 103 Results

#### 104 *B/Yamagata* circulation from 2016/17–2019/20

105 The prevalence of *B/Yamagata* varied widely across seasons (Figure 1, Figure S1). *B/Yamagata* was most  
106 prevalent in 2016/17 and 2017/18, comprising approximately 16–22% of all influenza virus specimens  
107 with a known subtype or lineage (compared to 1% in 2018/19 and 2019/20). Among all influenza B virus  
108 specimens with known lineage (Table S1), there was an increase in *B/Yamagata* prevalence by age, and in  
109 every season the greatest proportions of *B/Yamagata* positive specimens were identified among adults  
110 50–64 years and ≥65 years (Figure 1). Overall, the 2016/17 to 2019/20 seasons captured periods of high  
111 and low *B/Yamagata* circulation in addition to moderate to high epidemic severity, and thus represented  
112 a variety of plausible epidemiological scenarios.


113



114

115 **Figure 1. Prevalence of influenza B/Yamagata viruses.** (Top) Percentage of all influenza A and B viruses with a  
116 known subtype or lineage that were identified as influenza B. (Bottom) Percentage of all influenza B viruses with a  
117 known lineage that were identified as influenza B/Yamagata. Error bars represent 95<sup>th</sup> percentiles of the simulated  
118 uncertainty distributions.

119



120

121

122

**Figure 2. Estimated impact of vaccination against influenza B/Yamagata.** (A) Estimates of disease burden in the absence of vaccination. (B) Estimates of disease burden prevented by vaccination. For (A) and (B), bars show point

123 *estimates and error bars show 95<sup>th</sup> percentile uncertainty intervals. (C) Percentage of B/Yamagata hospitalizations*  
124 *prevented by vaccination. (D) Percentage of all influenza hospitalizations averted that were prevented by*  
125 *vaccination against B/Yamagata.*

126

127 *Estimates of B/Yamagata burden with and without vaccination*

128 Across all seasons, we estimated that 22.9 million (95<sup>th</sup> percentile uncertainty interval: 20.5–28.9 million)  
129 illnesses, 10.6 million (9.47–13.3 million) medically-attended illnesses, 340,000 (285,000–486,000)  
130 hospitalizations, and 25,100 (17,400–47,800) deaths would have occurred due to B/Yamagata in the  
131 absence of vaccination. Of these, vaccination prevented an estimated 4.15 million (3.51–5.45 million)  
132 illnesses, 2.01 million (1.68–2.65 million) medically-attended illnesses, 58,500 (40,900–91,300)  
133 hospitalizations, and 4,070 (2,300–8,270) deaths. Unsurprisingly, the greatest burden and prevented  
134 burden was estimated for the 2016/17 and 2017/18 seasons when B/Yamagata was most prevalent  
135 (Figure 2A–B). In particular, we estimated that a total of 217,000 (169,000–334,000) hospitalizations and  
136 15,900 (9,010–36,200) deaths would have occurred during 2017/18 in the absence of vaccination.

137 Among age groups, adults  $\geq 65$  years were estimated to experience the greatest burden of severe  
138 disease (hospitalizations and deaths) in the absence of vaccination against B/Yamagata, with up to  
139 142,000 (88,800–264,000) hospitalizations and 13,100 (5,980–34,000) deaths occurring in a single  
140 season (2017/18). Results were similar when expressed as the rate of severe disease per 100,000  
141 population (Figure S2). Vaccination also prevented the most severe disease among adults  $\geq 65$  years. For  
142 example, in 2017/18, vaccination prevented 20,900 (6,460–46,200) hospitalizations and 1,940 (530–  
143 5,550) deaths due to B/Yamagata. Conversely, vaccination generally prevented the greatest percentage  
144 of B/Yamagata hospitalizations among children 6 months–4 years (22–50% across seasons; Figure 2C).  
145 This corresponded to up to 11% of all influenza-associated hospitalizations among young children,  
146 depending on the season (Figure 2D). Results were similar when we used one B/Yamagata prevalence  
147 estimate for all age groups, rather than age-specific estimates (Figure S3). Overall, our results suggest  
148 older adults may be at greatest risk of severe disease if B/Yamagata were to recirculate in the absence of  
149 vaccine-mediated protection.

150

## 151 **Discussion**

152 We estimated the impact of vaccination against B/Yamagata-associated outcomes by combining data on  
153 B/Yamagata prevalence from 2016–2020 with estimates of influenza B-associated illnesses,  
154 hospitalizations and deaths prevented by vaccination during the same period. Our estimates of burden  
155 prevented by vaccination, and burden that would have occurred without vaccination, were greatest in

156 2016/17 and 2017/18 due to high prevalence of B/Yamagata during those seasons. For all seasons,  
157 vaccination prevented the most severe disease among adults  $\geq 65$  years, who experienced the highest  
158 prevalence of B/Yamagata and are at increased risk of severe complications following influenza virus  
159 infection. In contrast, the greatest percent of severe disease was prevented among young children.  
160 Overall, our results highlight the importance of continued B/Yamagata surveillance, and readiness to  
161 respond to possible re-emergence, given the potential for substantial morbidity and mortality without  
162 vaccination, particularly among groups at increased risk of severe influenza-associated complications.

163 Our estimates of the impact of vaccination in mitigating the burden of influenza B/Yamagata can  
164 help inform assessments of the potential impacts if B/Yamagata were to return to circulation in the  
165 absence of vaccination-mediated protection. In seasons with high circulation of B/Yamagata, we  
166 estimated up to 217,000 hospitalizations and 15,900 deaths would have occurred in the absence of  
167 vaccination, including up to 142,000 hospitalizations and 13,100 deaths among adults  $\geq 65$  years. Since  
168 our estimates reflect disease burden in the presence of some level of population immunity to  
169 B/Yamagata, which may have declined since 2020 and/or may decline with its continued absence from  
170 circulation and removal from the vaccine, morbidity and mortality could be higher than we have  
171 reported. However, any realized burden will depend on many factors, including the prevalence of  
172 B/Yamagata relative to other influenza viruses, the strength of cross-protection induced by vaccination  
173 against B/Victoria, and levels and durations of pre-existing immunity to B/Yamagata conferred through  
174 prior infection or vaccination.

175 There are several limitations that should be considered in interpreting these results. First, we  
176 assumed VE against all influenza B viruses was reflective of VE against influenza B/Yamagata. This was  
177 likely true in 2016/17 and 2017/18 when B/Yamagata was the dominant influenza B lineage. Conversely,  
178 the prevalence of B/Yamagata was so low in 2018/19 and 2019/20 that a small change in VE is unlikely to  
179 have a substantial impact on our absolute estimates of burden prevented by vaccination. Second,  
180 information on influenza vaccination was self-reported for adults and parent-reported for children and  
181 may be subject to recall bias. However, self-reported seasonal influenza vaccination status for adults has  
182 been shown to have relatively high agreement with vaccination status ascertained from medical  
183 records<sup>12</sup>. Finally, we assumed all vaccinees received a formulation containing B/Yamagata. However,  
184 trivalent vaccines in 2016/17–2019/20 did not include B/Yamagata and were still in use in the United  
185 States, albeit at declining levels relative to quadrivalent vaccines (for example, in 2017/18, 97% of Flu VE  
186 Network participants aged  $< 65$  years with known vaccine type received a quadrivalent inactivated  
187 vaccine)<sup>9,13–15</sup>. Data on trivalent vaccination coverage were not available for all age groups and seasons to



188 directly account for this in our framework, and our estimates of burden prevented by vaccination, and  
189 thus our estimates of burden without vaccination, may be overestimated if there was less vaccine-  
190 mediated cross-protection against B/Yamagata than we have assumed. However, our methods are also  
191 conservative in that they do not account for indirect effects of vaccination in reducing infection risks  
192 through herd immunity.

193 We have found that vaccination against B/Yamagata prevented substantial morbidity and  
194 mortality during seasons in which the virus circulated at high levels, particularly for adults  $\geq 65$  years.  
195 Continued surveillance for B/Yamagata recirculation will be important given its potential to cause  
196 substantial morbidity and mortality in the absence of vaccination.

197

198 **Funding:** This research did not receive any specific grant from funding agencies in the public,  
199 commercial, or not-for-profit sectors.

200

201 **Conflicts of Interest:** The authors have no competing interests to declare.

202

203 **Author Contributions:** All authors attest they meet the ICMJE criteria for authorship.

204

205 **Data availability statement:** All data were the result of secondary analyses. The majority are publicly  
206 available and cited within in the text. A small portion are not publicly available due to privacy restrictions  
207 but are available upon reasonable request to the authors.

208

## 209 **References**

210 1. Fiore AE, Uyeki TM, Broder K, et al. Prevention and control of influenza with vaccines: recommendations of the  
211 Advisory Committee on Immunization Practices (ACIP), 2010. *MMWR Recomm Rep Morb Mortal Wkly Rep*  
212 *Recomm Rep.* 2010;59(RR-8):1-62.

213 2. Grohskopf LA, Uyeki TM, Bresee J, Cox NJ, Shimabukuro T. Prevention and control of influenza with vaccines:  
214 recommendations of the Advisory Committee on Immunization Practices (ACIP)--United States, 2012-13  
215 influenza season. *MMWR Morb Mortal Wkly Rep.* 2012;61(32):613-618.

216 3. CDC. Trivalent Influenza Vaccines. 2024. Accessed October 3, 2024. [https://www.cdc.gov/flu/vaccine-](https://www.cdc.gov/flu/vaccine-types/trivalent.html)  
217 [types/trivalent.html](https://www.cdc.gov/flu/vaccine-types/trivalent.html)

218 4. Tokars JI, Rolfes MA, Foppa IM, Reed C. An evaluation and update of methods for estimating the number of  
219 influenza cases averted by vaccination in the United States. *Vaccine.* 2018;36(48):7331-7337.  
220 doi:10.1016/j.vaccine.2018.10.026



- 221 5. Morris SE, Mathis SM, Chung JR, et al. Estimating historical disease burden and the impact of vaccination by  
222 influenza type and subtype in the United States, 2016-2020. *medRxiv*. Published online October 28,  
223 2024:2024.10.25.24316040. doi:10.1101/2024.10.25.24316040
- 224 6. CDC. FluView Interactive. 2023. Accessed February 14, 2024. [https://www.cdc.gov/fluview/overview/fluview-](https://www.cdc.gov/fluview/overview/fluview-interactive.html)  
225 [interactive.html](https://www.cdc.gov/fluview/overview/fluview-interactive.html)
- 226 7. CDC. Past Flu Season Severity Assessments. 2024. Accessed March 25, 2024.  
227 <https://www.cdc.gov/flu/php/surveillance/past-seasons.html>
- 228 8. Paget J, Caini S, Riccio MD, Waarden W van, Meijer A. Has influenza B/Yamagata become extinct and what  
229 implications might this have for quadrivalent influenza vaccines? *Eurosurveillance*. 2022;27(39):2200753.  
230 doi:10.2807/1560-7917.ES.2022.27.39.2200753
- 231 9. Rolfes MA, Flannery B, Chung JR, et al. Effects of Influenza Vaccination in the United States During the 2017–  
232 2018 Influenza Season. *Clin Infect Dis*. 2019;69(11):1845-1853. doi:10.1093/cid/ciz075
- 233 10. Kostova D, Reed C, Finelli L, et al. Influenza Illness and Hospitalizations Averted by Influenza Vaccination in the  
234 United States, 2005–2011. *PLOS ONE*. 2013;8(6):e66312. doi:10.1371/journal.pone.0066312
- 235 11. Chung JR, Rolfes MA, Flannery B, et al. Effects of Influenza Vaccination in the United States During the 2018–  
236 2019 Influenza Season. *Clin Infect Dis Off Publ Infect Dis Soc Am*. 2020;71(8):e368-e376.  
237 doi:10.1093/cid/ciz1244
- 238 12. Rolnick SJ, Parker ED, Nordin JD, et al. Self-report compared to electronic medical record across eight adult  
239 vaccines: Do results vary by demographic factors? *Vaccine*. 2013;31(37):3928-3935.  
240 doi:10.1016/j.vaccine.2013.06.041
- 241 13. Flannery B, Chung JR, Monto AS, et al. Influenza Vaccine Effectiveness in the United States During the 2016–  
242 2017 Season. *Clin Infect Dis*. 2019;68(11):1798-1806. doi:10.1093/cid/ciy775
- 243 14. Grohskopf LA. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory  
244 Committee on Immunization Practices — United States, 2019–20 Influenza Season. *MMWR Recomm Rep*.  
245 2019;68. doi:10.15585/mmwr.rr6803a1
- 246 15. Grohskopf LA. Prevention and Control of Seasonal Influenza with Vaccines: Recommendations of the Advisory  
247 Committee on Immunization Practices—United States, 2018–19 Influenza Season. *MMWR Recomm Rep*.  
248 2018;67. doi:10.15585/mmwr.rr6703a1
- 249